Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson Oxytrol approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Watson is stressing the favorable side effect profile of its overactive bladder patch Oxytrol compared to oral anticholinergic medications like Pharmacia's Detrol LA (tolterodine) and Alza's Ditropan XL (oxybutynin). FDA approved Watson's oxybutynin transdermal system Feb. 26 for treatment of OAB with symptoms of urge urinary incontinence, urgency and frequency. Labeling notes that "in two pivotal studies, no patient discontinued Oxytrol treatment due to dry mouth." Detrol and Ditropan labeling note discontinuation rates of 2.4% and 1.2%, respectively. The Oxytrol patch delivers 3.9 mg oxybutynin per day for up to four day
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel